INDIGO Biosciences launches human 5-HT2A reporter assay

INDIGO Biosciences has added a human serotonin 2A receptor reporter assay to its neuroscience drug discovery portfolio. The new kit is designed to help researchers measure functional receptor activity in neuropsychiatric and serotonergic drug programs without building an internal assay from scratch.

Why it matters: - The Human Serotonin 2A Receptor (5-HT2A) Reporter Assay gives drug discovery teams a standardized way to evaluate a key neuropsychiatric target. - The assay is aimed at programs studying schizophrenia, psychosis, major depressive disorder, substance use disorders, psychedelic therapeutics and secondary pharmacology. - The launch expands INDIGO Biosciences’ cell-based assay portfolio for pharmaceutical and biotechnology customers working on serotonergic and neuropsychiatric medicines.

What happened: - INDIGO Biosciences announced the availability of its Human Serotonin 2A Receptor (5-HT2A) Reporter Assay on October 22, 2026. - The release came from State College, Pennsylvania. - The company said the new assay broadens its functional testing offerings for neuropsychiatric drug discovery, serotonergic pharmacology and secondary pharmacology screening.

The details: - The all-inclusive kit includes 5-HT2A reporter cells, optimized media, serotonin as a reference agonist, luciferase detection reagents and a cell culture-ready 96-well plate. - The assay is built for functional receptor testing, not just binding studies. - INDIGO Biosciences said the product eliminates the need for teams to develop, transfect and optimize an internal reporter system. - The company said the assay can help teams generate reproducible functional data within existing drug discovery workflows. - Dr. Andrew Woodman said the assay provides a standardized, ready-to-use method for measuring receptor activity and can reduce the time and resources needed to build an assay internally.

Between the lines: - Interest in 5-HT2A has increased as researchers look at serotonergic psychedelics and other new treatment approaches for difficult psychiatric conditions. - The receptor has long been linked to schizophrenia and psychosis and is inhibited by many atypical antipsychotic drugs. - INDIGO Biosciences is positioning the assay as part of a broader push into next-generation therapeutic development where functional receptor characterization is a key screening step.

What's next: - Drug discovery teams can now add the 5-HT2A assay into neuropsychiatric, psychedelic and serotonergic screening workflows. - INDIGO Biosciences is likely to continue expanding its portfolio of cell-based reporter assays as investment and clinical research in these areas grow. - The company is offering the assay as a standardized option for evaluating how candidate compounds modulate the 5-HT2A receptor.